<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="correction"><?properties open_access?><!-- Original-type: cg--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">2853103</article-id><article-id pub-id-type="pii">6605632</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6605632</article-id><article-categories><subj-group subj-group-type="heading"><subject>Corrigendum</subject></subj-group></article-categories><title-group><article-title>Glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia is associated with a proliferative metabolism</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Beesley</surname><given-names>A H</given-names></name></contrib><contrib contrib-type="author"><name><surname>Firth</surname><given-names>M J</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ford</surname><given-names>J</given-names></name></contrib><contrib contrib-type="author"><name><surname>Weller</surname><given-names>R E</given-names></name></contrib><contrib contrib-type="author"><name><surname>Freitas</surname><given-names>J R</given-names></name></contrib><contrib contrib-type="author"><name><surname>Perera</surname><given-names>K U</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kees</surname><given-names>U R</given-names></name></contrib></contrib-group><pub-date pub-type="epub"><day>30</day><month>03</month><year>2010</year></pub-date><pub-date pub-type="ppub"><day>30</day><month>03</month><year>2010</year></pub-date><volume>102</volume><issue>7</issue><fpage>1200</fpage><lpage>1200</lpage><copyright-statement>Copyright 2010, Cancer Research UK</copyright-statement><copyright-year>2010</copyright-year><permissions><copyright-holder>Cancer Research UK</copyright-holder></permissions><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="corrected-article" id="N0x36cb650N0x37ba7f0" ext-link-type="doi" xlink:href="10.1038/sj.bjc.6605072"/></article-meta></front><body><p><bold>Correction to</bold>: <italic>British Journal of Cancer</italic> (2009) <bold>100</bold>, 1926&#x02013;1936; doi:<related-article related-article-type="corrected-article" id="N0x36cb650N0x37badf0" ext-link-type="doi" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="10.1038/sj.bjc.6605072">10.1038/sj.bjc.6605072</related-article></p><p>In reference to <xref ref-type="fig" rid="fig4">Figure 4D</xref>, the drug quercetin is clearly cytotoxic as a single agent in the ALL-SIL cell line, but its effect in combination with dexamethasone (DEX) is not synergistic as originally quoted. Rather, the combination of quercetin and DEX resulted in a small, though non-significant reduction in cytotoxicity. This is in contrast to resveratrol (<xref ref-type="fig" rid="fig4">Figure 4E</xref>), which demonstrated synergistic cytotoxicity in combination with DEX. This difference in the two agents is reflected in their connectivity map (CMAP) enrichment scores in <xref rid="tbl3" ref-type="table">Table 3</xref>, with quercetin showing a positive enrichment in contrast to the negative scores for resveratrol, LY-294002 and rapamycin. Both quercetin and resveratrol are polyphenols that activate the key metabolic regulator AMPK, but the results suggest that they are mechanistically different and are unlikely to be equally efficacious in combinatorial therapy with glucocorticoids in T-cell acute lymphoblastic leukaemia (T-ALL). <xref ref-type="fig" rid="fig4">Figure 4D</xref> and <xref rid="tbl3" ref-type="table">Table 3</xref> from the original paper are reproduced for reference, below.</p></body><floats-wrap><fig id="fig4"><label>Figure 4</label><caption><p>Synergy of CMAP-identified drugs with DEX in T-ALL cell lines. Graphs show cell survival following 48&#x02009;h incubation. Comparisons were made in each data set to the respective control condition, which was set to 100&#x00025;. Vehicle control (C) and the following drug treatments were analysed: (D) 10&#x02009;m<sc>M</sc> (Q10), 25&#x02009;m<sc>M</sc> (Q25) quercetin and 1&#x02009;m<sc>M</sc> DEX (D1) in ALL-SIL.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" mime-subtype="eps" xlink:href="6605632f4"/></fig><table-wrap id="tbl3" position="float"><label>Table 3</label><caption><p content-type="table-title">CMAP drugs significantly associated with MPRED- and DEX-resistance gene signatures in T-ALL cell lines</p></caption><table frame="hsides" rules="groups" border="1" width="85%"><colgroup><col align="left"/><col align="left"/><col align="char" char="."/><col align="char" char="."/><col align="left"/><col align="left"/><col align="char" char="."/><col align="char" char="."/></colgroup><thead valign="bottom"><tr><th colspan="4" align="center" valign="top" charoff="50"><bold>MPRED</bold></th><th colspan="4" align="center" valign="top" charoff="50"><bold>DEX</bold></th></tr><tr><th align="left" valign="top" charoff="50"><bold>Drug</bold></th><th align="left" valign="top" charoff="50"><bold>Mechanism of action</bold></th><th align="center" valign="top" char="." charoff="50"><bold>Enrichment</bold></th><th align="center" valign="top" char="." charoff="50"><bold><italic>P</italic>-value</bold></th><th align="left" valign="top" charoff="50"><bold>Drug</bold></th><th align="left" valign="top" charoff="50"><bold>Mechanism of action</bold></th><th align="center" valign="top" char="." charoff="50"><bold>Enrichment</bold></th><th align="center" valign="top" char="." charoff="50"><bold><italic>P</italic>-value</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">LY-294002</td><td align="left" valign="top" charoff="50">AKT/PI3K inhibitor</td><td align="char" valign="top" char="." charoff="50">&#x02212;0.507</td><td align="char" valign="top" char="." charoff="50">0.0001</td><td align="left" valign="top" charoff="50">Rapamycin</td><td align="left" valign="top" charoff="50">mTOR inhibitor</td><td align="char" valign="top" char="." charoff="50">&#x02212;0.653</td><td align="char" valign="top" char="." charoff="50">&#x0003c;0.0001</td></tr><tr><td align="left" valign="top" charoff="50">Trichostatin A</td><td align="left" valign="top" charoff="50">HDAC inhibitor</td><td align="char" valign="top" char="." charoff="50">&#x02212;0.423</td><td align="char" valign="top" char="." charoff="50">0.018</td><td align="left" valign="top" charoff="50">Geldenamycin</td><td align="left" valign="top" charoff="50">HSP90 inhibitor</td><td align="char" valign="top" char="." charoff="50">0.655</td><td align="char" valign="top" char="." charoff="50">0.004</td></tr><tr><td align="left" valign="top" charoff="50">Carbamazepine</td><td align="left" valign="top" charoff="50">Antiepileptic</td><td align="char" valign="top" char="." charoff="50">&#x02212;0.792</td><td align="char" valign="top" char="." charoff="50">0.020</td><td align="left" valign="top" charoff="50">LY-294002</td><td align="left" valign="top" charoff="50">AKT/PI3K inhibitor</td><td align="char" valign="top" char="." charoff="50">&#x02212;0.397</td><td align="char" valign="top" char="." charoff="50">0.005</td></tr><tr><td align="left" valign="top" charoff="50">W-13</td><td align="left" valign="top" charoff="50">Calmodulin antagonist</td><td align="char" valign="top" char="." charoff="50">0.903</td><td align="char" valign="top" char="." charoff="50">0.021</td><td align="left" valign="top" charoff="50">Sodium phenylbutyrate</td><td align="left" valign="top" charoff="50">HDAC inhibitor</td><td align="char" valign="top" char="." charoff="50">&#x02212;0.564</td><td align="char" valign="top" char="." charoff="50">0.014</td></tr><tr><td align="left" valign="top" charoff="50">Blebbistatin</td><td align="left" valign="top" charoff="50">Myosin II inhibitor</td><td align="char" valign="top" char="." charoff="50">&#x02212;0.896</td><td align="char" valign="top" char="." charoff="50">0.023</td><td align="left" valign="top" charoff="50">Quercetin</td><td align="left" valign="top" charoff="50">ROS scavenger/antioxidant</td><td align="char" valign="top" char="." charoff="50">0.903</td><td align="char" valign="top" char="." charoff="50">0.019</td></tr><tr><td align="left" valign="top" charoff="50">Wortmannin</td><td align="left" valign="top" charoff="50">AKT/PI3K inhibitor</td><td align="char" valign="top" char="." charoff="50">&#x02212;0.497</td><td align="char" valign="top" char="." charoff="50">0.024</td><td align="left" valign="top" charoff="50">Resveratrol</td><td align="left" valign="top" charoff="50">ROS scavenger/antioxidant</td><td align="char" valign="top" char="." charoff="50">&#x02212;0.630</td><td align="char" valign="top" char="." charoff="50">0.020</td></tr><tr><td align="left" valign="top" charoff="50">Benserazide</td><td align="left" valign="top" charoff="50">Amino-acid decarboxylase inhibitor</td><td align="char" valign="top" char="." charoff="50">0.885</td><td align="char" valign="top" char="." charoff="50">0.028</td><td align="left" valign="top" charoff="50">Cobalt chloride</td><td align="left" valign="top" charoff="50">Hypoxia mimetic</td><td align="char" valign="top" char="." charoff="50">&#x02212;0.742</td><td align="char" valign="top" char="." charoff="50">0.037</td></tr><tr><td align="left" valign="top" charoff="50">Rapamycin</td><td align="left" valign="top" charoff="50">mTOR inhibitor</td><td align="char" valign="top" char="." charoff="50">&#x02212;0.441</td><td align="char" valign="top" char="." charoff="50">0.031</td><td align="left" valign="top" charoff="50">Fludrocortisone</td><td align="left" valign="top" charoff="50">Steroid</td><td align="char" valign="top" char="." charoff="50">0.857</td><td align="char" valign="top" char="." charoff="50">0.042</td></tr><tr><td align="left" valign="top" charoff="50">Indomethacin</td><td align="left" valign="top" charoff="50">Cyclo-oxygenase inhibitor</td><td align="char" valign="top" char="." charoff="50">0.662</td><td align="char" valign="top" char="." charoff="50">0.031</td><td align="left" valign="top" charoff="50">Deferoxamine</td><td align="left" valign="top" charoff="50">Hypoxia mimetic</td><td align="char" valign="top" char="." charoff="50">&#x02212;0.717</td><td align="char" valign="top" char="." charoff="50">0.049</td></tr><tr><td align="left" valign="top" charoff="50">Quercetin</td><td align="left" valign="top" charoff="50">ROS scavenger/antioxidant</td><td align="char" valign="top" char="." charoff="50">0.876</td><td align="char" valign="top" char="." charoff="50">0.033</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Y-27632</td><td align="left" valign="top" charoff="50">Rho-kinase inhibitor</td><td align="char" valign="top" char="." charoff="50">&#x02212;0.872</td><td align="char" valign="top" char="." charoff="50">0.036</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Tamoxifen</td><td align="left" valign="top" charoff="50">Oestrogen-receptor blocker</td><td align="char" valign="top" char="." charoff="50">0.740</td><td align="char" valign="top" char="." charoff="50">0.039</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Resveratrol</td><td align="left" valign="top" charoff="50">ROS scavenger/antioxidant</td><td align="char" valign="top" char="." charoff="50">&#x02212;0.583</td><td align="char" valign="top" char="." charoff="50">0.040</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td><td align="char" valign="top" char="." charoff="50">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="t3-fn1"><label/><p>Data indicate the CMAP-calculated enrichment score and permuted <italic>P</italic>-value for association with GC expression profiles.</p></fn></table-wrap-foot></table-wrap></floats-wrap></article>


